ResMed Inc (BSP:R1MD34)
R$ 371.16 0 (0%) Market Cap: 217.94 Bil Enterprise Value: 220.49 Bil PE Ratio: 33.02 PB Ratio: 7.04 GF Score: 85/100

Resmed Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 08:20PM GMT
Release Date Price: R$180.38
Lyanne Harrison
BofA Merrill Lynch, Research Division - VP

Hi Rob, I'll get started. Hello, all, and welcome to our conversation with ResMed. My name is Lyanne Harrison, and I'm Bank of America's Australian Health Care Analyst. As you heard, Rob Douglas is also on the phone. He's the COO of ResMed. And Rob held that role of Chief Operating Officer since September 2011. So thank you all for joining us today. Rob, are you still there?

Robert A. Douglas
ResMed Inc. - President & COO

Yes. Yes, Lyanne. I'm sorry for jumping the gun there.

Lyanne Harrison
BofA Merrill Lynch, Research Division - VP

That's all right. That's all right. Why don't you start by taking us -- telling us a little bit more about ResMed?

Robert A. Douglas
ResMed Inc. - President & COO

Sure. Thanks, Lyanne. Just wanted to quickly recap our recent earnings and talk to a little bit about our strategy. ResMed, we've really focused on respiratory care. And in this time of crisis with the COVID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot